Human serum (healthy, pancreatitis and pancreas cancer) |
Regulation of sialylated subset of the N-glyco-proteome in pancreatitis and pancreas cancer |
Synapt G2 HDMS Q-TOF |
Beam-type CID (N/A) |
Qualitative (GlycopeptideID) and quantitative (label-free XIC, int. standard) |
Protein concentrations measured separately |
62/27/17 |
Kontro et al., 2014 (104) |
Human embryonic kidney (HEK293T cells) |
In-depth N-glycoproteome analysis of the widely used HEK293T cells |
LTQ-Orbitrap Velos |
HCD (DDA) |
Qualitative (manual) |
De-N-glycoproteome also profiled |
177/82/N/A |
Chen et al., 2014 (94) |
Human serum |
Site-specific analysis of serum N-glycoproteome |
LTQ-OrbitrapXL |
Ion trap CID and HCD (DDA) |
Qualitative (GRIP) and quantitative (label-free spectral count) |
De-N-glycoproteome also profiled + serum N-glycome database generated |
183/37/24 |
Liu et al., 2014 (159) |
Cynomolgus monkey plasma |
In-depth site-specific analysis of monkey plasma N-glycoproteome |
QSTAR XL, TripleTOF 5600 Q-TOF |
Beam-type CID (DIA) |
Qualitative (Byonic/manual) |
Proteome database generated |
705/254/130 |
Zhao et al., 2014 (135) |
Human cystic fibrosis sputum |
Discovery of unconventi-onal class of human N-gly-coproteins (paucimannose, Man1–3Fuc0–1-GlcNAc2) |
Orbitrap-Elite |
Ion trap CID, HCD and ETD (DDA) |
Qualitative (Byonic) and quantitative (label-free XIC) |
N-glycome and proteome also profiled |
115/36/30 |
Thaysen-Andersen et al., 2015 (21) |
Human cerebrospinal fluid |
“Brain-type” N-glycoproteome signature of CSF |
Maxis UHR Q-TOF |
Beam-type CID (DDA) |
Qualitative (GlycoQuest in ProteinScape) |
N-glycome, proteome and de-N-glycoproteome also profiled |
124/55/36 |
Goyallon et al., 2015 (162) |
Human urinary exosomes |
First site-specific analysis of the urinary exosome N-glycoproteome |
Synapt G2 HDMS Q-TOF |
Beam-type CID (N/A) |
Qualitative (GlycopeptideID) |
N-glycome also profiled |
126/51/37 |
Saraswat et al., 2015 (88) |
Human fetal lung fibroblast (TIG-1–20 cells) |
In-depth site-specific analysis of the fibroblast membrane N-glycoproteome (comparison to serum) |
LTQ-FT |
Ion trap CID (DDA) |
Qualitative (manual) and quantitative (label-free XIC) |
De-N-glycoproteome also profiled |
272/63/44 |
Takakura et al., 2015 (103) |
Mouse heart tissue (WT vs transverse aortic constriction) |
Regulation of the N-glycoproteome in response to transverse aortic constriction |
Orbitrap Q-Exactive |
HCD (DDA) |
Qualitative (Proteome Discoverer, GPQuest) and quantitative (iTRAQ) |
N-glycome, proteome and de-N-glycoproteome also profiled |
291/N/A/195 |
Yang et al., 2015 (108) |
Mouse liver |
Tissue-specific N-glycoproteome signature from mouse liver relative to mouse brain |
LTQ-Orbitrap Velos |
HCD and ETD (DDA) |
Qualitative (Protein Prospector) |
Data compared qualitatively to mouse brain N- and O-glycoproteome |
534/168/106 |
Medzihradszky et al., 2015 (13) |
Mouse kidney (WT and FUT9 knock out) |
Lewis X regulation of N-glycoproteome in FUT9 knock-out mice |
LTQ-Orbitrap |
HCD (DDA) |
Qualitative (in-house program) |
N-glycome and de-N-glycoproteome profiled, glycopeptides desialy-lated prior to profiling |
591/70/48 |
Noro et al., 2015 (107) |
Human prostate cancer cell cultures (LNCaP and PC3 cells) |
Androgen-dependent N-glycosylation signatures in prostate cancer |
Orbitrap Q-Exactive |
HCD (DDA) |
Qualitative (Byonic and GPQuest) and quantitative (iTRAQ) |
Proteome and de-N-glycoproteome also profiled |
1145/N/A/227 |
Shah et al., 2015 (46) |
Mouse adipocyte cultures (WT and insulin resistant (IR) 3T3-L1 cells) |
IR-induced N-glyco-proteome regulation (galactose and sialylation switching) |
Orbitrap-Fusion |
Ion trap CID, HCD, EThcD (DDA) |
Qualitative (Byonic) and quantitative (SILAC) |
N-glycome, proteome and de-N-glycoproteome also profiled |
1580/332/154 |
Parker et al., 2016 (105) |
Human seminal plasma |
First deeper investigation of the N-glycoproteome of human seminal plasma |
Synapt G2 HDMS Q-TOF |
Beam-type CID (DDA) |
Qualitative (GlycopeptideID) |
N/A |
243/73/50 |
Saraswat et al., 2016 (87) |